benzinga.com
Embecta Rallies After UK Firm Deal Worth $200 Million
This strategic move aims to enhance Embecta's capabilities in drug-delivery systems.
Embecta Corp.EMBCNASDAQ
Loading
Latest News
Loading news...
globenewswire.com
embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited
Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad‑based medical supplies company Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad‑based medical supplies company
defenseworld.net
Reviewing Pacific Health Care Organization (OTCMKTS:PFHO) & Embecta (NASDAQ:EMBC)
Pacific Health Care Organization (OTCMKTS:PFHO - Get Free Report) and Embecta (NASDAQ: EMBC - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability. Analyst Ratings This is a summary
globenewswire.com
embecta names new Chairman of the Board and Lead Independent Director
PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the “Board”) of embecta has elected Devdatt “Dev” Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately.
fool.com
3 Healthcare Stocks Paying the Highest Dividends of 2026
Despite an 8.2% forward yield, be careful with Perrigo, due to its value trap reputation. Yielding 6.7%, Pfizer is a strong choice among high-yield dividend stocks, given the company's post-COVID-19 catalysts.
defenseworld.net
Embecta (NASDAQ:EMBC) Shares Gap Up After Strong Earnings
Shares of Embecta Corp. (NASDAQ: EMBC - Get Free Report) gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $11.35, but opened at $12.61. Embecta shares last traded at $11.34, with a volume of 254,893 shares traded. The company reported $0.71 earnings
seekingalpha.com
Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript
globenewswire.com
Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results
PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results.
globenewswire.com
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock.
gurufocus.com
Yacktman Fund's Strategic Moves: A Closer Look at Samsung Electronics Co Ltd
Insights from the Fourth Quarter of 2025 Yacktman Fund (Trades, Portfolio) recently submitted the N-PORT filing for the fourth quarter of 2025, providing insig
globenewswire.com
embecta to Report Fiscal First Quarter Financial Results
PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026.
seekingalpha.com
Embecta Corp. (EMBC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Embecta Corp. (EMBC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
defenseworld.net
Comparing Embecta (NASDAQ:EMBC) & Organon & Co. (NYSE:OGN)
Organon and Co. (NYSE: OGN - Get Free Report) and Embecta (NASDAQ: EMBC - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Valuation and Earnings This table compares Organon and
defenseworld.net
Nutex Health (NASDAQ:NUTX) & Embecta (NASDAQ:EMBC) Head to Head Survey
Embecta (NASDAQ: EMBC - Get Free Report) and Nutex Health (NASDAQ: NUTX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Analyst Recommendations This is a summary of current
globenewswire.com
embecta to Participate at the J.P. Morgan 2026 Healthcare Conference
PARSIPPANY, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P.
defenseworld.net
Head to Head Analysis: Embecta (NASDAQ:EMBC) vs. GoodRx (NASDAQ:GDRX)
Embecta (NASDAQ: EMBC - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Earnings and Valuation This table compares Embecta and GoodRx"s
seekingalpha.com
Embecta Growth Stalls Despite Strong Fiscal 2025 Results (Rating Downgrade)
Embecta Corp. (EMBC) faces a challenging fiscal 2026, with flat revenue and earnings growth expected - after a strong fiscal 2025. EMBC's weak outlook is driven by cannula costs, modest volume declines, and higher R&D expenses, despite improved margins and debt reduction. The dividend yield of 4.77% may appeal to income investors, but near-term growth prospects remain limited, warranting a Hold rating.
seekingalpha.com
Meet 33 Ideal "Safer" November Small/MidCap Value DiviBuys Of The S&P600
The S&P 600 Small/MidCap index offers high-yield dividend opportunities, with 33 out of 53 top-yielding stocks meeting both the 'safer' and IDEAL dividend Dogcatcher criteria. Top ten S&P600 dividend 'dogs' are projected to deliver 24% to 93% net gains by November 2026, based on analyst targets and current yields. Stocks like KNTK, SM, CRGY, and DEI stand out for strong total return potential, but investors should beware of negative free cash flow in some high-yield picks.
seekingalpha.com
Embecta Corp. (EMBC) Q4 2025 Earnings Call Transcript
Embecta Corp. ( EMBC ) Q4 2025 Earnings Call November 25, 2025 8:00 AM EST Company Participants Pravesh Khandelwal - VP & Head of Investor Relations Devdatt Kurdikar - President, CEO & Director Jake Elguicze - Senior VP & CFO Conference Call Participants Marie Thibault - BTIG, LLC, Research Division Michael Polark - Wolfe Research, LLC Anthony Petrone - Mizuho Securities USA LLC, Research Division Gracia Mahoney - BofA Securities, Research Division Presentation Operator Welcome, ladies and gentlemen, to Embecta Corp.'s Fiscal Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and a replay will be available on the company's website following the call.
globenewswire.com
Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance
PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2025.